| scholarly article | Q13442814 |
| P50 | author | Nigel Mackman | Q37828857 |
| P2093 | author name string | A Phillip Owens | |
| P2860 | cites work | Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque | Q24339425 |
| No evidence for tissue factor on platelets | Q24634305 | ||
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Prothrombotic markers and early spontaneous recanalization in ST-segment elevation myocardial infarction | Q28220222 | ||
| Laser-induced noninvasive vascular injury models in mice generate platelet- and coagulation-dependent thrombi | Q28364326 | ||
| Microvesicle-associated tissue factor and Trousseau's syndrome | Q29026182 | ||
| Tissue factor-dependent coagulation is preferentially up-regulated within arterial branching areas in a baboon model of Escherichia coli sepsis | Q30477051 | ||
| Monocyte-bound PF4 in the pathogenesis of heparin-induced thrombocytopenia | Q30497774 | ||
| Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle P-selectin glycoprotein ligand 1 and platelet P-selectin | Q31144359 | ||
| Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation | Q33379387 | ||
| Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. | Q33491071 | ||
| Carbohydrates and activity of natural and recombinant tissue factor | Q33517083 | ||
| Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques | Q33520612 | ||
| Detection of endogenous tissue factor levels in plasma using the calibrated automated thrombogram assay | Q33679124 | ||
| Platelet microparticles: a wide-angle perspective | Q33706238 | ||
| The role of tissue factor and factor VIIa in hemostasis | Q33728350 | ||
| Levels of microparticle tissue factor activity correlate with coagulation activation in endotoxemic mice | Q33728358 | ||
| Contribution of host-derived tissue factor to tumor neovascularization | Q33765271 | ||
| Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer | Q33765406 | ||
| Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice | Q34052621 | ||
| Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. | Q34291730 | ||
| The tissue factor requirement in blood coagulation | Q34360277 | ||
| Intracellular and surface distribution of monocyte tissue factor: application to intersubject variability | Q34469955 | ||
| Role of the extrinsic pathway of blood coagulation in hemostasis and thrombosis | Q34635642 | ||
| Role of tissue factor in venous thrombosis. | Q34795476 | ||
| Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque | Q58071677 | ||
| Cellular Origins and Thrombogenic Activity of Microparticles Isolated From Human Atherosclerotic Plaques | Q58149183 | ||
| Shed Membrane Microparticles With Procoagulant Potential in Human Atherosclerotic Plaques | Q58150410 | ||
| Circulating tissue factor accumulates in thrombi, but not in hemostatic plugs | Q61404983 | ||
| Shedding of tissue factor (TF)-containing microparticles rather than alternatively spliced TF is the main source of TF activity released from human cancer cells. | Q64930704 | ||
| A bleeding disorder characterised by isolated deficiency of platelet microvesicle generation. | Q64963767 | ||
| Tumor shedding and coagulation | Q70662680 | ||
| Tissue factor pathway inhibitor | Q70943593 | ||
| Procoagulant activity and active calpain in platelet-derived microparticles | Q71506045 | ||
| Identification of active tissue factor in human coronary atheroma | Q71571184 | ||
| Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide | Q71647217 | ||
| The Nature and Significance of Platelet Products in Human Plasma | Q72220665 | ||
| Mechanism of tissue factor activation on HL-60 cells | Q73292508 | ||
| Platelet-associated tissue factor contributes to the collagen-triggered activation of blood coagulation | Q73445675 | ||
| Tissue factor pathway inhibitor: potential therapeutic applications | Q73447508 | ||
| Inhibition of tissue factor limits the growth of venous thrombus in the rabbit | Q73690584 | ||
| Cell-derived microparticles circulate in healthy humans and support low grade thrombin generation | Q73848313 | ||
| Real-time in vivo imaging of platelets, tissue factor and fibrin during arterial thrombus formation in the mouse | Q74817597 | ||
| Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome | Q75202209 | ||
| Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina | Q77846342 | ||
| Evidence for activation of tissue factor by an allosteric disulfide bond | Q79141196 | ||
| Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer | Q79478642 | ||
| Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension | Q79843837 | ||
| Human platelets synthesize and express functional tissue factor | Q79906781 | ||
| Blood borne tissue factor revisited | Q80118442 | ||
| Fibronectin-adherent monocytes express tissue factor and tissue factor pathway inhibitor whereas endotoxin-stimulated monocytes primarily express tissue factor: physiologic and pathologic implications | Q80241135 | ||
| Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation | Q80388691 | ||
| Macrovascular thrombosis is driven by tissue factor derived primarily from the blood vessel wall | Q80512468 | ||
| Tissue factor activity in whole blood | Q81157689 | ||
| A murine model of deep vein thrombosis: characterization and validation in transgenic mice | Q81438680 | ||
| Granulocytes do not express but acquire monocyte-derived tissue factor in whole blood: evidence for a direct transfer | Q81463987 | ||
| Soluble tissue factor is a candidate marker for progression of microvascular disease in patients with Type 2 diabetes | Q82050367 | ||
| Increased levels of procoagulant tissue factor-bearing microparticles within the occluded coronary artery of patients with ST-segment elevation myocardial infarction: role of endothelial damage and leukocyte activation | Q83010127 | ||
| Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism | Q83266217 | ||
| MPs or ICs? | Q83313311 | ||
| Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer | Q83983985 | ||
| Microparticle-associated tissue factor activity in cancer patients with and without thrombosis | Q84009686 | ||
| Tissue factor activity of blood mononuclear cells is increased after total knee arthroplasty | Q84637495 | ||
| The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII. | Q41858297 | ||
| Protein disulfide isomerase acts as an injury response signal that enhances fibrin generation via tissue factor activation | Q41975370 | ||
| Expression of tissue factor, thrombomodulin, and E-selectin in baboons with lethal Escherichia coli sepsis | Q41992252 | ||
| Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. | Q42138675 | ||
| Plasma thrombomodulin activity, tissue factor activity and high levels of circulating procoagulant phospholipid as prognostic factors for acute myocardial infarction | Q43266070 | ||
| Platelets, circulating tissue factor, and fibrin colocalize in ex vivo thrombi: real-time fluorescence images of thrombus formation and propagation under defined flow conditions | Q44155368 | ||
| Elevated numbers of tissue-factor exposing microparticles correlate with components of the metabolic syndrome in uncomplicated type 2 diabetes mellitus | Q44205749 | ||
| Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. | Q44654420 | ||
| Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin | Q44836521 | ||
| Cellular origin and procoagulant properties of microparticles in meningococcal sepsis | Q44952875 | ||
| Detached endothelial cells and microparticles as sources of tissue factor activity | Q46669220 | ||
| P-selectin and leukocyte microparticles are associated with venous thrombogenesis | Q47400180 | ||
| The biological significance of the thromboplastic protein of blood. | Q47807987 | ||
| Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes | Q47835134 | ||
| Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa. | Q47963574 | ||
| Induction of microparticle- and cell-associated intravascular tissue factor in human endotoxemia. | Q48028694 | ||
| Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model | Q49970213 | ||
| Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction | Q50357082 | ||
| Cell-derived microparticles in haemostasis and vascular medicine. | Q50616202 | ||
| Inferior vena cava ligation rapidly induces tissue factor expression and venous thrombosis in rats | Q50616637 | ||
| Murine thrombosis models. | Q51251127 | ||
| Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction | Q51558965 | ||
| Leukocyte- and platelet-derived microparticles correlate with thrombus weight and tissue factor activity in an experimental mouse model of venous thrombosis. | Q51732019 | ||
| Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma | Q51779640 | ||
| Assessment of plasma tissue factor activity in patients presenting with coronary artery disease: limitations of a commercial assay | Q51818616 | ||
| Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes | Q52538187 | ||
| Hyperlipidemia promotes thrombosis after injury to atherosclerotic vessels in apolipoprotein E-deficient mice | Q52539967 | ||
| Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice | Q52543322 | ||
| Lactadherin deficiency leads to apoptotic cell accumulation and accelerated atherosclerosis in mice | Q52578310 | ||
| A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. | Q53598537 | ||
| Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. | Q53781843 | ||
| Cell-derived vesicles exposing coagulant tissue factor in saliva | Q56851614 | ||
| Leukocyte-versus microparticle-mediated tissue factor transfer during arteriolar thrombus development | Q57375038 | ||
| Tissue factor expression on platelets is a dynamic event | Q57398744 | ||
| Blood coagulation dynamics in haemostasis. | Q35154489 | ||
| Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury | Q36007691 | ||
| Signal-dependent splicing of tissue factor pre-mRNA modulates the thrombogenicity of human platelets. | Q36228070 | ||
| Tissue-specific hemostasis in mice | Q36241086 | ||
| Tissue factor encryption | Q36362231 | ||
| Procoagulant microparticles: disrupting the vascular homeostasis equation? | Q36600785 | ||
| Development and validation of a predictive model for chemotherapy-associated thrombosis | Q36657982 | ||
| Tissue factor activity is increased in a combined platelet and microparticle sample from cancer patients | Q36947164 | ||
| Regulation of tissue factor procoagulant activity by post-translational modifications | Q37055665 | ||
| Vascular smooth muscle-derived tissue factor is critical for arterial thrombosis after ferric chloride-induced injury | Q37066276 | ||
| Lactadherin and clearance of platelet-derived microvesicles | Q37086945 | ||
| C5a and TNF-alpha up-regulate the expression of tissue factor in intra-alveolar neutrophils of patients with the acute respiratory distress syndrome | Q37170021 | ||
| Blood-borne tissue factor: another view of thrombosis | Q37181879 | ||
| Cancer cell-derived microparticles bearing P-selectin glycoprotein ligand 1 accelerate thrombus formation in vivo. | Q37331535 | ||
| The significance of shed membrane particles during programmed cell death in vitro, and in vivo, in HIV-1 infection | Q37365561 | ||
| Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. | Q37438142 | ||
| Tissue factor in coagulation: Which? Where? When? | Q37438302 | ||
| Tissue factor expression in blood cells | Q37690913 | ||
| Why do cells release vesicles? | Q37691032 | ||
| Tissue factor and thrombosis models | Q37731195 | ||
| Predictive value of tissue factor bearing microparticles in cancer associated thrombosis. | Q37740321 | ||
| Microparticles: protagonists of a novel communication network for intercellular information exchange | Q37804649 | ||
| Overcoming limitations of microparticle measurement by flow cytometry | Q37806990 | ||
| Tissue factor and its measurement in whole blood, plasma, and microparticles | Q37806995 | ||
| Platelet- and megakaryocyte-derived microparticles | Q37806997 | ||
| Cellular Mechanisms Underlying the Formation of Circulating Microparticles | Q37821168 | ||
| Tissue factor-bearing microparticles and thrombus formation | Q37830928 | ||
| Transcriptional regulation of tissue factor expression in human endothelial cells | Q38295839 | ||
| Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: studies using a new digital flow cytometer | Q39781488 | ||
| Microparticle-associated tissue factor activity: a link between cancer and thrombosis? | Q40260694 | ||
| Tissue-factor-bearing microvesicles arise from lipid rafts and fuse with activated platelets to initiate coagulation. | Q40452110 | ||
| Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis | Q40502054 | ||
| Interaction of P-selectin and PSGL-1 generates microparticles that correct hemostasis in a mouse model of hemophilia A. | Q40575096 | ||
| Scott syndrome: a disorder of platelet coagulant activity. | Q40577010 | ||
| Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism | Q40824665 | ||
| Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor | Q40868860 | ||
| P433 | issue | 10 | |
| P921 | main subject | thrombosis | Q261327 |
| P304 | page(s) | 1284-1297 | |
| P577 | publication date | 2011-05-01 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Microparticles in hemostasis and thrombosis | |
| P478 | volume | 108 |
| Q90093656 | 2-Aminoethoxydiphenylborate (2-APB) inhibits release of phosphatidylserine-exposing extracellular vesicles from platelets |
| Q37444651 | 4-Hydroxy-2-Nonenal Enhances Tissue Factor Activity in Human Monocytic Cells via p38 Mitogen-Activated Protein Kinase Activation-Dependent Phosphatidylserine Exposure |
| Q38121367 | A glimpse of the glomerular milieu: From endothelial cell to thrombotic disease in nephrotic syndrome |
| Q35544658 | A matched cross-sectional study of the association between circulating tissue factor activity, immune activation and advanced liver fibrosis in hepatitis C infection |
| Q90403197 | A new assay to evaluate microvesicle plasmin generation capacity: validation in disease with fibrinolysis imbalance |
| Q35125841 | A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles |
| Q36928587 | A novel pathway of cellular activation mediated by antiphospholipid antibody-induced extracellular vesicles |
| Q102054083 | A review of the role of extracellular vesicles in neonatal physiology and pathology |
| Q38845946 | A review of the venous thrombotic issues associated with multiple myeloma |
| Q43186030 | A simple flow cytometry method improves the detection of phosphatidylserine-exposing extracellular vesicles |
| Q33711653 | Abnormal P-selectin localization during megakaryocyte development determines thrombosis in the gata1low model of myelofibrosis |
| Q38516928 | Accelerated RBC senescence as a novel pathologic mechanism of blood stasis syndrome in traditional East Asian medicine |
| Q33600393 | Action of Nanoparticles on Platelet Activation and Plasmatic Coagulation |
| Q33438155 | Activated platelet-derived and leukocyte-derived circulating microparticles and the risk of thrombosis in heparin-induced thrombocytopenia: A role for pf4-bearing microparticles? |
| Q41137228 | Activation of Endothelial Pro-resolving Anti-Inflammatory Pathways by Circulating Microvesicles from Non-muscular Myosin Light Chain Kinase-Deficient Mice |
| Q92741776 | Acute effects of haemodialysis on circulating microparticles |
| Q58088027 | Aerobic glycolysis fuels platelet activation: small-molecule modulators of platelet metabolism as anti-thrombotic agents |
| Q40582473 | Aging- and activation-induced platelet microparticles suppress apoptosis in monocytic cells and differentially signal to proinflammatory mediator release |
| Q48272685 | Agonist-induced platelet reactivity correlates with bleeding in haemato-oncological patients |
| Q90678936 | Algorithms for managing coagulation disorders in liver disease |
| Q37990195 | All cut up! The consequences of calpain activation on platelet function |
| Q36193691 | An Integrated Fluid-Chemical Model Toward Modeling the Formation of Intra-Luminal Thrombus in Abdominal Aortic Aneurysms |
| Q38644253 | An overview of the role of microparticles/microvesicles in blood components: Are they clinically beneficial or harmful? |
| Q35949830 | Are microparticles the missing link between thrombosis and autoimmune diseases? Involvement in selected rheumatologic diseases. |
| Q37953778 | Arterial thrombosis—insidious, unpredictable and deadly |
| Q35987865 | Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism |
| Q38104276 | Association of microparticles and preeclampsia |
| Q35611763 | Biological properties of extracellular vesicles and their physiological functions. |
| Q92853263 | Biology and Role of Extracellular Vesicles (EVs) in the Pathogenesis of Thrombosis |
| Q38919574 | Biology and biogenesis of shed microvesicles |
| Q39381245 | Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease |
| Q47708491 | Brain-Derived Microparticles in Patients with Severe Isolated TBI. |
| Q35220670 | Brain-derived microparticles induce systemic coagulation in a murine model of traumatic brain injury |
| Q87868008 | CD18-mediated adhesion is required for the induction of a proinflammatory phenotype in lung epithelial cells by mononuclear cell-derived extracellular vesicles |
| Q37558436 | Cancer and Thrombosis: The Platelet Perspective. |
| Q48573415 | Caspase inhibition reduces hepatic tissue factor-driven coagulation in vitro and in vivo |
| Q34937666 | Cathepsin G-dependent modulation of platelet thrombus formation in vivo by blood neutrophils |
| Q93108843 | Cell Type- and Exposure-Specific Modulation of CD63/CD81-Positive and Tissue Factor-Positive Extracellular Vesicle Release in response to Respiratory Toxicants |
| Q34160603 | Cellular microparticle and thrombogram phenotypes in the Prospective Observational Multicenter Major Trauma Transfusion (PROMMTT) study: correlation with coagulopathy |
| Q39280011 | Cellular microparticles and pathophysiology of traumatic brain injury |
| Q53477651 | Characterization of Natural IgM Antibodies Recognizing Oxidation-Specific Epitopes on Circulating Microvesicles |
| Q51767823 | Characterization of microparticles in patients with venous malformations of the head and neck |
| Q36346156 | Circulating Microparticles Alter Formation, Structure, and Properties of Fibrin Clots. |
| Q51644749 | Circulating Microparticles Decrease After Cardiac Stress in Patients With Significant Coronary Artery Stenosis. |
| Q89537829 | Circulating Tissue Factor-Positive Procoagulant Microparticles in Patients with Type 1 Diabetes |
| Q34902070 | Circulating endothelial cells and procoagulant microparticles in patients with glioblastoma: prognostic value. |
| Q39618962 | Circulating microparticles and the risk of thromboembolic events in Egyptian beta thalassemia patients |
| Q35014306 | Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies |
| Q39314024 | Circulating microparticles generate and transport monomeric C-reactive protein in patients with myocardial infarction. |
| Q34749444 | Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. |
| Q46344026 | Circulating platelet and erythrocyte microparticles in young children and adolescents with sickle cell disease: Relation to cardiovascular complications. |
| Q91839670 | Clinical Significance of Factor XIII Activity and Monocyte-Derived Microparticles in Cancer Patients |
| Q41144530 | Clinical significance of circulating microparticles in Ph- myeloproliferative neoplasms |
| Q36661960 | Coagulation activation in sickle cell trait: an exploratory study |
| Q27021049 | Coagulation and the vessel wall in pulmonary embolism |
| Q39443587 | Coagulopathy and haemorrhagic progression in traumatic brain injury: advances in mechanisms, diagnosis, and management |
| Q38670276 | Comparison of the release of microRNAs and extracellular vesicles from platelets in response to different agonists |
| Q33425421 | Complement Interactions with Blood Cells, Endothelial Cells and Microvesicles in Thrombotic and Inflammatory Conditions |
| Q37906322 | Crosstalk between cancer and haemostasis. Implications for cancer biology and cancer-associated thrombosis with focus on tissue factor |
| Q83567626 | Del-etion of Microvesicles From the Circulation |
| Q35542696 | Detection and quantification of microparticles from different cellular lineages using flow cytometry. Evaluation of the impact of secreted phospholipase A2 on microparticle assessment |
| Q35069625 | Detection of tissue factor antigen and coagulation activity in coronary artery thrombi isolated from patients with ST-segment elevation acute myocardial infarction |
| Q36368068 | Differences of microparticle patterns between sickle cell anemia and hemoglobin SC patients |
| Q41141303 | Different Potential of Extracellular Vesicles to Support Thrombin Generation: Contributions of Phosphatidylserine, Tissue Factor, and Cellular Origin |
| Q52560150 | Differential Interaction of Platelet-Derived Extracellular Vesicles with Leukocyte Subsets in Human Whole Blood. |
| Q84445081 | Differential ability of tissue factor antibody clones on detection of tissue factor in blood cells and microparticles |
| Q43623723 | Dose-related Differences in the Pharmacodynamic and Toxicologic Response to a Novel Hyperglycosylated Analog of Recombinant Human Erythropoietin in Sprague-Dawley Rats with Similarly High Hematocrit |
| Q38578543 | Dosing of rivaroxaban by indication: getting the right dose for the patient. |
| Q47328598 | Dynamics of circulating microparticles in obesity after weight loss. |
| Q53431937 | Effect of blood microparticles on the kinetics of polymerization and enzymatic hydrolysis of fibrin |
| Q93133348 | Effects of Cryopreservation on Microparticles Concentration, Procoagulant Function, Size Distribution, and Morphology |
| Q52915225 | Effects of lipid-lowering treatment on circulating microparticles in patients with diabetes mellitus and chronic kidney disease |
| Q88692135 | Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms |
| Q38138876 | Emerging paradigms in arterial thrombosis |
| Q35646481 | Endogenous pro-thrombotic biomarkers from the arm and leg may not have the same value |
| Q90655353 | Endothelial cell apoptosis and the role of endothelial cell-derived extracellular vesicles in the progression of atherosclerosis |
| Q50072140 | Endothelial cell-derived microvesicles: potential mediators and biomarkers of pathologic processes. |
| Q45416461 | Endothelial cells but not platelets are the major source of Toll-like receptor 4 in the arterial thrombosis and tissue factor expression in mice |
| Q53121379 | Endothelial microparticles increase in mitral valve disease and impair mitral valve endothelial function |
| Q38001993 | Endothelial microparticles: missing link in endothelial dysfunction? |
| Q35624092 | Endothelial microparticles: sophisticated vesicles modulating vascular function |
| Q36011477 | Endothelial progenitor cells in atherosclerosis |
| Q90652758 | Endothelial- and Immune Cell-Derived Extracellular Vesicles in the Regulation of Cardiovascular Health and Disease |
| Q48502412 | Enhanced Procoagulant Activity on Blood Cells after Acute Ischemic Stroke |
| Q83463033 | Evidence for direct transfer of tissue factor from monocytes to platelets in whole blood |
| Q27022210 | Evolving Role of Microparticles in the Pathophysiology of Endothelial Dysfunction |
| Q35146268 | Excess of heme induces tissue factor-dependent activation of coagulation in mice |
| Q57192749 | Exercise during hemodialysis does not affect the phenotype or prothrombotic nature of microparticles but alters their proinflammatory function |
| Q48225900 | Exosomes and microvesicles in normal physiology, pathophysiology, and renal diseases. |
| Q49942942 | Exosomes as Diagnostic Biomarkers in Cardiovascular Diseases |
| Q54217653 | Extracellular Vesicles as Carriers of Non-coding RNAs in Liver Diseases |
| Q104136970 | Extracellular Vesicles as Unique Signaling Messengers: Role in Lung Diseases |
| Q49196893 | Extracellular Vesicles in Cardiovascular Theranostics. |
| Q37517034 | Extracellular vesicle protein levels are related to brain atrophy and cerebral white matter lesions in patients with manifest vascular disease: the SMART-MR study |
| Q38954563 | Extracellular vesicles in liver pathobiology: Small particles with big impact. |
| Q39453434 | Extracellular vesicles in renal disease |
| Q60955768 | Extracellular vesicles: biomarkers and regulators of vascular function during extracorporeal circulation |
| Q36803149 | Extracellular vesicles: communication, coercion, and conditioning |
| Q97526719 | Extracellular vesicles: novel communicators in lung diseases |
| Q35991236 | Factor V Leiden and Inflammation |
| Q92924544 | Factor XII-Deficient Chicken Plasma as a Useful Target for Screening of Pro- and Anticoagulant Animal Venom Toxins |
| Q57976976 | Factor Xa dimerization competes with prothrombinase complex formation on platelet-like membrane surfaces |
| Q47135651 | Fibrin-bearing microparticles: marker of thrombo-embolic events in pancreatic and colorectal cancers |
| Q50319342 | Flow analysis of individual blood extracellular vesicles in acute coronary syndrome |
| Q90308858 | From Classical Laboratory Parameters to Novel Biomarkers for the Diagnosis of Venous Thrombosis |
| Q38736928 | From glioblastoma to endothelial cells through extracellular vesicles: messages for angiogenesis. |
| Q38145557 | Gateway to understanding microparticles: standardized isolation and identification of plasma membrane-derived vesicles |
| Q42856814 | Glioblastoma microvesicles promote endothelial cell proliferation through Akt/beta-catenin pathway. |
| Q36405104 | Hepatocyte tissue factor contributes to the hypercoagulable state in a mouse model of chronic liver injury |
| Q27024964 | Hyperlipidemia, tissue factor, coagulation, and simvastatin |
| Q57559233 | Imaging and Therapeutic Potential of Extracellular Vesicles |
| Q30458303 | Imaging flow cytometry elucidates limitations of microparticle analysis by conventional flow cytometry |
| Q34893956 | Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability |
| Q37316399 | Impact of endothelial microparticles on coagulation, inflammation, and angiogenesis in age-related vascular diseases |
| Q38289218 | Impact of platelet phenotype on myocardial infarction. |
| Q34560286 | Increased promyelocytic-derived microparticles: a novel potential factor for coagulopathy in acute promyelocytic leukemia |
| Q38689619 | Influence of red blood cell-derived microparticles upon vasoregulation |
| Q26861577 | Infusible platelet membrane as a platelet substitute for transfusion: an overview |
| Q89957134 | Interactions between neutrophil extracellular traps and activated platelets enhance procoagulant activity in acute stroke patients with ICA occlusion |
| Q38099667 | Interplay between coagulation and vascular inflammation in sickle cell disease |
| Q88192190 | Intracellular origin and ultrastructure of platelet-derived microparticles |
| Q55399104 | Investigation of procoagulant activity in extracellular vesicles isolated by differential ultracentrifugation. |
| Q45807873 | Is a decrease of microparticles related to improvement of hemostasis after FVIII injection in hemophilia A patients treated on demand? |
| Q38072506 | Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges |
| Q55352821 | Iso-Osmolar Iodixanol Induces Less Increase in Circulating Endothelial Microparticles In Vivo and Less Endothelial Apoptosis In Vitro Compared with Low-Osmolar Iohexol. |
| Q58708585 | Lab-on-Chip for Exosomes and Microvesicles Detection and Characterization |
| Q47957279 | Lactadherin Promotes Microvesicle Clearance to Prevent Coagulopathy and Improves Survival of Severe TBI Mice |
| Q86852555 | Leukocyte-Derived Microparticles as Proinflammatory Mediators in Atherosclerosis |
| Q84010046 | Making contact with microparticles |
| Q90652641 | Matrix Signaling Subsequent to a Myocardial Infarction: A Proteomic Profile of Tissue Factor Microparticles |
| Q38836079 | Measurement of extracellular vesicles as biomarkers of consequences or cause complications of pathological states, and prognosis of both evolution and therapeutic safety/efficacy |
| Q33422771 | Mechanism of Platelet Activation and Hypercoagulability by Antithymocyte Globulins (ATG). |
| Q97520716 | Mechanisms and biomarkers of cancer-associated thrombosis |
| Q37955206 | Mechanisms and clinical implications of thrombosis in paroxysmal nocturnal hemoglobinuria |
| Q35738656 | Mechanisms of thrombogenesis in polycythemia vera |
| Q34255409 | Mechanistic View of Risk Factors for Venous Thromboembolism |
| Q52648131 | Membrane properties involved in calcium-stimulated microparticle release from the plasma membranes of S49 lymphoma cells. |
| Q49210192 | Message in a Microbottle: Modulation of Vascular Inflammation and Atherosclerosis by Extracellular Vesicles |
| Q38364069 | Microparticle analysis in disorders of hemostasis and thrombosis |
| Q35968665 | Microparticle-Induced Coagulation Relates to Coronary Artery Atherosclerosis in Severe Aortic Valve Stenosis |
| Q91581837 | Microparticle-associated tissue factor activity in dogs with disseminated intravascular coagulation |
| Q39626842 | Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. |
| Q84210387 | Microparticles and Paracrine Signaling in Portal Hypertension: Crucial Conversations or Idle Chat? |
| Q38021265 | Microparticles and acute lung injury |
| Q38874997 | Microparticles as biomarkers of venous thromboembolic events |
| Q35928145 | Microparticles as immune regulators in infectious disease - an opinion |
| Q38823104 | Microparticles in sickle cell anaemia: promise and pitfalls |
| Q37363894 | Microparticles in the blood of patients with systemic lupus erythematosus (SLE): phenotypic characterization and clinical associations |
| Q34991385 | Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection |
| Q37032283 | Microparticles variability in fresh frozen plasma: preparation protocol and storage time effects. |
| Q38242740 | Microparticles: new light shed on the understanding of venous thromboembolism. |
| Q37014088 | Microvesicle Tissue Factor Activity and Interleukin-8 Levels are Associated with Mortality in Patients with Influenza A/H1N1 Infection |
| Q36388098 | Microvesicle phenotypes are associated with transfusion requirements and mortality in subjects with severe injuries |
| Q38078430 | Microvesicles as risk markers for venous thrombosis |
| Q39000052 | Modulating thrombotic diathesis in hereditary thrombophilia and antiphospholipid antibody syndrome: a role for circulating microparticles? |
| Q64237035 | Molecular Mechanisms Underpinning Microparticle-Mediated Cellular Injury in Cardiovascular Complications Associated with Diabetes |
| Q52584136 | Molecular interactions at the surface of extracellular vesicles. |
| Q85224492 | Monocyte count associated with subsequent symptomatic venous thromboembolism (VTE) in hospitalized patients with solid tumors |
| Q92645809 | Monocyte procoagulant responses to anthrax peptidoglycan are reinforced by proinflammatory cytokine signaling |
| Q40679113 | Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin |
| Q27300845 | Nano-zymography Using Laser-Scanning Confocal Microscopy Unmasks Proteolytic Activity of Cell-Derived Microparticles |
| Q34425335 | Neurokinin 1 receptor mediates membrane blebbing and sheer stress-induced microparticle formation in HEK293 cells |
| Q37589724 | Neutrophil-derived microparticles are released into the coronary circulation following percutaneous coronary intervention in acute coronary syndrome patients |
| Q38072904 | New Fundamentals in Hemostasis |
| Q36068279 | New insights into the mechanisms of venous thrombosis |
| Q55652396 | New players in haemostasis and thrombosis. |
| Q51493562 | Non-contact acoustic capture of microparticles from small plasma volumes |
| Q88535298 | Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease |
| Q28088373 | Novel methodologies for biomarker discovery in atherosclerosis |
| Q39180438 | Novel proteolytic microvesicles released from human macrophages after exposure to tobacco smoke |
| Q53425363 | Ovarian cancer-derived extracellular vesicles affect normal human fibroblast behavior |
| Q36207807 | P2X7 regulation of macrophage tissue factor activity and microparticle generation |
| Q33400120 | PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. |
| Q33842909 | Peptides derived from MARCKS block coagulation complex assembly on phosphatidylserine. |
| Q55379791 | Pharmacokinetics of Human Red Blood Cell Microparticles Prepared Using High-Pressure Extrusion Method. |
| Q36728170 | Phosphatidylserine exposing-platelets and microparticles promote procoagulant activity in colon cancer patients |
| Q94600467 | Phosphatidylserine positive microparticles improve hemostasis in in-vitro hemophilia A plasma models |
| Q37625070 | Phospholipid-dependent procoagulant activity is highly expressed by circulating microparticles in patients with essential thrombocythemia |
| Q37575309 | Physical biology in cancer. 2. The physical biology of circulating tumor cells |
| Q49495752 | Physiologic Impact of Circulating RBC Microparticles upon Blood-Vascular Interactions |
| Q37514497 | Plasma concentration of platelet-derived microparticles is related to painful vaso-occlusive phenotype severity in sickle cell anemia |
| Q37585586 | Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications |
| Q38392023 | Plasma-derived Extracellular Vesicles Contain Predictive Biomarkers and Potential Therapeutic Targets for Myocardial Ischemic (MI) Injury. |
| Q90133870 | Platelet P-selectin triggers rapid surface exposure of tissue factor in monocytes |
| Q53411184 | Platelet and not erythrocyte microparticles are procoagulant in transfused thalassaemia major patients. |
| Q35124116 | Platelet count measured prior to cancer development is a risk factor for future symptomatic venous thromboembolism: the Tromsø Study |
| Q50673192 | Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis |
| Q85574310 | Platelet microparticles: reinforcing the hegemony of platelets in atherothrombosis |
| Q39094993 | Platelet microvesicles in health and disease |
| Q46094023 | Platelet-Derived Microparticles and Platelet Function Profile in Children With Congenital Heart Disease |
| Q47106708 | Platelet-Derived Microvesicles in Cardiovascular Diseases. |
| Q57183566 | Platelet-derived microparticles are implicated in remote ischemia conditioning in a rat model of cerebral infarction |
| Q36236572 | Platelet-derived microparticles generated by neonatal extracorporeal membrane oxygenation systems. |
| Q38836975 | Platelet-derived microparticles regulates thrombin generation via phophatidylserine in abdominal sepsis |
| Q38817491 | Platelet-derived microparticles trigger THP-1 monocytic cell aggregation and release of pro-coagulant tissue factor-expressing microparticles in vitro |
| Q91496613 | Platelet-derived- Extracellular Vesicles Promote Hemostasis and Prevent the Development of Hemorrhagic Shock |
| Q99556353 | Platelets Can Associate with SARS-Cov-2 RNA and Are Hyperactivated in COVID-19 |
| Q37969498 | Platelets and Primary Haemostasis |
| Q38542454 | Platelets and Their Interactions with Other Immune Cells |
| Q36058568 | Platelets and platelet-like particles mediate intercellular RNA transfer |
| Q57676581 | Platelets as immune-sensing cells |
| Q104440632 | Platelets can contain SARS-CoV-2 RNA and are hyperactivated in COVID-19 |
| Q41166174 | Platelets microparticles as a link between micro- and macro-angiopathy in young patients with type 1 diabetes |
| Q34660102 | Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted phospholipase A2 to promote inflammation |
| Q36653460 | Post splenectomy related pulmonary hypertension. |
| Q93092127 | Postprandial Increase in Blood Plasma Levels of Tissue Factor-Bearing (and Other) Microvesicles Measured by Flow Cytometry: Fact or Artifact? |
| Q45355715 | Potassium leakage primes stored erythrocytes for phosphatidylserine exposure and shedding of pro‐coagulant vesicles |
| Q61816605 | Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models |
| Q64938047 | Predictive potential of haemostatic biomarkers for venous thromboembolism in cancer patients. |
| Q35690807 | Procoagulant activity in hemostasis and thrombosis: Virchow's triad revisited |
| Q50959065 | Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia |
| Q41700530 | Procoagulant and platelet-derived microvesicle absolute counts determined by flow cytometry correlates with a measurement of their functional capacity |
| Q36909379 | Procoagulant microparticles promote coagulation in a factor XI-dependent manner in human endotoxemia |
| Q35158964 | Procoagulant, tissue factor-bearing microparticles in bronchoalveolar lavage of interstitial lung disease patients: an observational study |
| Q42875405 | Prostate Cancer-Associated Disseminated Intravascular Coagulation with Excessive Fibrinolysis Treated with Degarelix |
| Q37720933 | Proteomic analysis of microparticles isolated from malaria positive blood samples |
| Q24315760 | Proteomic analysis of microvesicles from plasma of healthy donors reveals high individual variability |
| Q63914995 | Proteomic analysis reveals procoagulant properties of cigarette smoke-induced extracellular vesicles |
| Q38448646 | Proteomic characteristics of circulating microparticles in patients with newly-diagnosed type 2 diabetes |
| Q38077297 | Prothrombotic mechanisms and anticoagulant therapy in dogs with immune-mediated hemolytic anemia |
| Q39653052 | Quantitative Proteome Profiling of Normal Human Circulating Microparticles |
| Q38375370 | Quantitative proteome analysis of plasma microparticles for the characterization of HCV-induced hepatic cirrhosis and hepatocellular carcinoma. |
| Q45875415 | Recombinant human factor VIIa (rFVIIa) in hemophilia: mode of action and evidence to date. |
| Q50499084 | Red blood cell-derived microparticles isolated from blood units initiate and propagate thrombin generation |
| Q55237882 | Redox-dependent thiol modifications: implications for the release of extracellular vesicles. |
| Q36572590 | Regulation of tissue factor coagulant activity on cell surfaces |
| Q50434203 | Release and cellular origin of extracellular vesicles during circulation of whole blood over adsorbent polymers for lipid apheresis. |
| Q38801779 | Review of the Association between Splenectomy and Chronic Thromboembolic Pulmonary Hypertension. |
| Q38842491 | Review: the Multiple Roles of Monocytic Microparticles |
| Q38117725 | Revisited role of microparticles in arterial and venous thrombosis. |
| Q27016431 | Role of plasma kallikrein in diabetes and metabolism |
| Q41522512 | Role of procoagulant microparticles in mediating complications and outcome of acute liver injury/acute liver failure |
| Q34612375 | Role of tissue factor in Mycobacterium tuberculosis-induced inflammation and disease pathogenesis |
| Q38034092 | Role of tissue factor in atherothrombosis |
| Q92239589 | Self-DNA at the Epicenter of SLE: Immunogenic Forms, Regulation, and Effects |
| Q48101047 | Serum Exosomes Attenuate H2O2-Induced Apoptosis in Rat H9C2 Cardiomyocytes via ERK1/2. |
| Q37141019 | Serum extracellular vesicle protein levels are associated with acute coronary syndrome |
| Q47174785 | Small-size platelet microparticles trigger platelet and monocyte functionality and modulate thrombogenesis via P-selectin |
| Q37996577 | Sources of tissue factor that contribute to thrombosis after rupture of an atherosclerotic plaque |
| Q37648414 | Splenectomy is modifying the vascular remodeling of thrombosis |
| Q53216740 | Stimulation of blood mononuclear cells with bacterial virulence factors leads to the release of pro-coagulant and pro-inflammatory microparticles |
| Q26999377 | Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes |
| Q92535745 | The Contrasting Role of Extracellular Vesicles in Vascular Inflammation and Tissue Repair |
| Q94554098 | The Course of Circulating Small Extracellular Vesicles in Patients Undergoing Surgical Aortic Valve Replacement |
| Q41513485 | The ESCRT-III pathway facilitates cardiomyocyte release of cBIN1-containing microparticles |
| Q36564652 | The Impact of Lipoprotein-Associated Oxidative Stress on Cell-Specific Microvesicle Release in Patients with Familial Hypercholesterolemia. |
| Q64973377 | The Release of Monocyte-Derived Tissue Factor-Positive Microparticles Contributes to a Hypercoagulable State in Idiopathic Membranous Nephropathy. |
| Q27021748 | The central role of extracellular vesicles in the mechanisms of thrombosis in paroxysmal nocturnal haemoglobinuria: a review |
| Q38624868 | The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease |
| Q41071373 | The effect of corn trypsin inhibitor, anti-tissue factor pathway inhibitor antibodies and phospholipids on microvesicle-associated thrombin generation in patients with pancreatic cancer and healthy controls. |
| Q35108949 | The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers |
| Q38184831 | The emerging roles of microvesicles in liver diseases |
| Q47572596 | The hemostatic activity of cryopreserved platelets is mediated by phosphatidylserine-expressing platelets and platelet microparticles |
| Q33766511 | The involvement of cation leaks in the storage lesion of red blood cells |
| Q38083929 | The platelet–cancer loop |
| Q38034249 | The potential of flavanol and procyanidin intake to influence age-related vascular disease |
| Q57170189 | The role of neutrophils in thrombosis |
| Q39032612 | The role of platelet microvesicles in intercellular communication. |
| Q26801407 | The role of platelets in the recruitment of leukocytes during vascular disease |
| Q33412254 | Therapeutic drug-induced platelet apoptosis: an overlooked issue in pharmacotoxicology |
| Q64075350 | There Is Selective Increase in Pro-thrombotic Circulating Extracellular Vesicles in Acute Ischemic Stroke and Transient Ischemic Attack: A Study of Patients From the Middle East and Southeast Asia |
| Q61814938 | Thrombin Generation and Cancer: Contributors and Consequences |
| Q42248974 | Thrombin generation assay and transmission electron microscopy: a useful combination to study tissue factor-bearing microvesicles |
| Q50193700 | Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms |
| Q58805706 | Thrombus Formation and Propagation in the Onset of Cardiovascular Events |
| Q49418460 | Tissue Factor-bearing MPs and the risk of venous thrombosis in cancer patients: A meta-analysis |
| Q37991794 | Tissue factor controversies |
| Q34544801 | Tissue factor in tumor microenvironment: a systematic review |
| Q40942192 | Tissue factor is induced by interleukin-33 in human endothelial cells: a new link between coagulation and inflammation |
| Q90702701 | Tissue factor procoagulant activity in the tumor cell lines and plasma of dogs with various malignant tumors |
| Q35923274 | Tissue factor-dependent and -independent pathways of systemic coagulation activation in acute myeloid leukemia: a single-center cohort study |
| Q48465547 | Tissue-factor-bearing microparticles (MPs-TF) in patients with acute ischaemic stroke: the influence of stroke treatment on MPs-TF generation. |
| Q38205945 | Toward routine detection of extracellular vesicles in clinical samples |
| Q38127152 | Transplantation of xenogeneic islets: are we there yet? |
| Q28391580 | Traumatic Brain Injury-Associated Coagulopathy |
| Q41872549 | Trousseau's Syndrome, a Previously Unrecognized Condition in Acute Ischemic Stroke Associated With Myocardial Injury |
| Q37169096 | Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients |
| Q90713322 | Two-Color Analysis of Leukocytes Labeled by Modified RBCs and Their Fragments |
| Q89967655 | Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes |
| Q45126293 | Using annexin V-coated magnetic beads to capture active tissue factor-bearing microparticles from body fluids |
| Q38815146 | Using the laboratory to predict thrombosis in dogs: An achievable goal? |
| Q89217812 | Venous thrombosis |
| Q34984444 | White blood cell count measured prior to cancer development is associated with future risk of venous thromboembolism--the Tromsø study |
Search more.